Clinical Trials | November 10, 2025
Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
Relmada expects to initiate its Phase 3 program in the first half of 2026
Relmada expects to initiate its Phase 3 program in the first half of 2026
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country
PET sheets are widely recognised for their superior clarity, strength, and barrier properties
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
AI-powered cardiometabolic wellness platform for India’s workforce
Subscribe To Our Newsletter & Stay Updated
